Nada El-Ekiaby

Dr. Nada El-Ekiaby

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2014 in Biomedical Reports
Verified
Journal Article
Open access
PDF file
SRSarah Ehab Riad
Sarah Ehab Riad
NENada El-Ekiaby
Nada El-Ekiaby
RMRadwa Yehia Mekky
Radwa Yehia Mekky
RARasha Ahmed
Rasha Ahmed
MDMohammad Ahmed Mohey EL Din
Mohammad Ahmed Mohey EL Din
AAAhmed Ihab Abdelaziz
Ahmed Ihab Abdelaziz
Hepatits C virus (HCV) genotype 4 (GT4) shows low treatment response rates and discrepancies when compared to other genotypes. However, the reason underlying these discrepancies remains unclear due to the limited number of studies on GT4. microRNA‑155 (miR‑155) is a noteworthy example of a discrepancy in GT4, as it was found to be upregulated in genotypes 1, 2 and 3 HCV infection, but downregulated in GT4‑HCV‑infected peripheral blood mononuclear cells (PBMCs). The present study aimed to investigate the expression of miR‑155 in PBMCs, serum and liver tissues of GT4‑HCV‑infected patients. miR‑155 expression was assessed using reverse transcription‑quantitative polymerase chain reaction in GT4‑HCV‑infected PBMCs, serum and liver tissues, as well as GT2‑ and GT4‑infected Huh7 cells, and compared to the healthy controls. There was no difference in miR‑155 expression observed between naïve GT4‑HCV patients and healthy controls in the PBMCs and serum. In HCV‑infected liver tissues, however, a significant downregulation was observed. The unique miR‑155 expression pattern during GT4 infection was confirmed in the infected Huh7 cell lines when compared to GT2 infection. Clinical data showed a positive correlation between liver transaminases and serum miR‑155 expression. In addition, serum miR‑155 expression was significantly lower in naïve non‑responders (NRs) than naïve sustained virological responders (SVRs), and in post‑treatment NRs compared to post‑treatment SVRs. In conclusion, miR‑155 was not only proven to be a genotype‑specific microRNA that is not induced during GT4‑HCV infection, but also a good prognostic factor and predictor of response to treatment enabling a non‑invasive differentiation between NRs and SVRs during GT4‑HCV infection.

13 August 2014 in Biomedical Reports
Verified
Journal Article
Open access
PDF file
DEDalia Sherif Elhelw
Dalia Sherif Elhelw
RMRadwa Yehia Mekky
Radwa Yehia Mekky
NENada El-Ekiaby
Nada El-Ekiaby
RARasha Ahmed
Rasha Ahmed
MEMohammad Ahmed Mohey Eldin
Mohammad Ahmed Mohey Eldin
AAAhmed Ihab Abdelaziz
Ahmed Ihab Abdelaziz
MicroRNA (miRNA) expression in organs does not always represent their quantity in serum. A disparity in the expression of miR‑181a has been reported in the tissues and serum of hepatocellular carcinoma (HCC) patients. Since hepatitis C virus (HCV) is a major cause of HCC and miR‑181a has never been studied in HCV, the present study aimed to investigate the miR‑181a expression profile in genotype 4 (GT4)‑HCV patients to evaluate whether this pattern is also apparent in HCV. RNA was extracted from liver tissues, peripheral mononuclear cells (PBMCs) and serum samples from GT4‑HCV‑infected patients and healthy donors to evaluate the relative miR‑181a expression using quantitative reverse transcription‑polymerase chain reaction. miR‑181a was significantly higher in the serum of naïve patients compared to controls, and an inverse correlation with the viral load and liver enzymes was apparent. By contrast, no difference in miR‑181a expression was observed in the liver tissues and PBMCs of patients compared to controls. This expression observed in HCV is conflicting to that previously reported in HCC. The study also demonstrates a significant upregulation of miR‑181a post‑interferon/ribavirin treatment in the serum of sustained virological responders (SVRs) compared to non‑responders and treatment‑naïve SVRs. In conclusion, miR‑181a may be considered to be a possible prognostic marker in GT4‑HCV infection.

16 January 2025 in Cells
Verified
Journal Article
Open access
PDF file
SFSalma A. Fahim
Salma A. Fahim
MRManon Ragheb
Manon Ragheb
IFIbrahim Hassan Fayed
Ibrahim Hassan Fayed
AOAya Osama
Aya Osama
AKAhmed Karam
Ahmed Karam
AAAhmed Ihab Abdelaziz
Ahmed Ihab Abdelaziz
Meis1 is a transcription factor involved in numerous functions including development and proliferation and has been previously shown to harness cell cycle progression. In this study, we used in silico analysis to predict that miR-499-5p targets Meis1 and that Malat1 sponges miR-499-5p. For the first time, we demonstrated that the overexpression of miR-499-5p led to the downregulation of Meis1 mRNA and protein in C166 cells by directly binding to its 3’UTR. Moreover, knocking down Malat1 increased miR-499-5p expression, subsequently suppressing Meis1. Through BrdU incorporation assay, we showed that the knockdown of Malat1, Meis1, or mimicking with miR-499-5p promoted cell proliferation. Enrichment analyses on proteins identified via mass spectrometry after manipulating Malat1, miR-499-5p, or Meis1 revealed a multitude of differentially expressed proteins related to cell cycle, cell division, and key pathways like Wnt and mTOR, essential for cell proliferation. Collectively, our findings confirm that Malat1 sponges miR-499-5p, regulating Meis1, and that Malat1/miR-499-5p/Meis1 could potentially form an axis that has a pivotal influence on cellular proliferation.

Verified
Journal Article
Open access
PDF file
AAAmira Khaled Abdelhamid
Amira Khaled Abdelhamid
FPFabiola Pedrini
Fabiola Pedrini
JSJennifer Schmitt
Jennifer Schmitt
IFIbrahim Hassan Fayed
Ibrahim Hassan Fayed
AOAya Osama
Aya Osama
NENada El-Ekiaby
Nada El-Ekiaby
Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ) are key regulators of hepatic stellate cell (HSC) activation and liver fibrosis. While the canonical YAP/TAZ-TEAD axis is well-characterized, non-canonical interaction partners and downstream long non-coding RNAs (lncRNAs) that orchestrate fibrogenic programs in HSCs remain undefined. Using BioID and next-generation sequencing (NGS) in LX-2 cells, we identified YAP/TAZ-interactomes and YAP/TAZ-regulated lncRNAs. BioID results and proximity ligation assay (PLA) identified the transcription factor Kaiso as a TAZ interaction partner. Functionally, Kaiso knockdown suppressed key aspects of HSC activation in LX-2 cells. We next integrated our NGS results from YAP/TAZ-knockdown in LX-2 cells with publicly available Kaiso ChIP-seq data. This identified HIF1A-AS3 as a common downstream lncRNA. ChIP-qPCR confirmed direct binding of Kaiso to the HIF1A-AS3 promoter. Furthermore, HIF1A-AS3 silencing mirrored the functional effects of Kaiso knockdown. Global proteomic profiling following knockdown of TAZ, Kaiso, or HIF1A-AS3 revealed a network of commonly regulated proteins enriched for pathways central to HSC activation. In conclusion, we establish Kaiso as a novel TAZ interaction partner and identify HIF1A-AS3 as a shared downstream target of TAZ and Kaiso, suggesting a potential profibrotic regulatory network that promotes HSC activation and may represent a therapeutic target for liver fibrosis.